pomalidomide Articles
US and European hema-oncologists views therapies for relapsed/refractory multiple myeloma
15 May 2013
FDA approves Celgene's Pomalyst for advanced multiple myeloma
11 February 2013
Celgene's pomalidomide meets MM-003 study endpoints
23 October 2012
Regulatory briefs: Celgene's pomalidomide; Lundbeck's vortioxetine
21 September 2012
Hematologist-oncologists view Velcade more favorably than Revlimid or Thalomid for multiple myeloma; report
1 November 2011
Showing 1-7 of 7 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
